[Propanc Biopharma, Inc.] Propanc Biopharma, Inc., a biopharmaceutical company developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells, announced it is advancing its clinical development program for PRP, its investigational proenzyme-based therapeutic candidate.

[Sumitomo Pharma America, Inc.] Sumitomo Pharma America, Inc. announced that the US FDA has granted Breakthrough Therapy designation to enzomenib for the treatment of patients with relapsed/refractory acute leukemia with KMT2A rearrangement (R/R KMT2Ar).

[Cardiff Oncology, Inc.] Cardiff Oncology, Inc. announced that the US FDA has granted Orphan Drug Designation to onvansertib for the treatment of patients with chronic myelomonocytic leukemia.

[Advanced Science] Researchers integrated single-nucleus RNA sequencing, spatial transcriptomics, and multiplex immunohistochemistry to elucidate the tumor microenvironment and mechanisms of relapse in no specific molecular profile endometrial cancer.

[Science Advances] The authors identified lactic acid, a highly abundant environmental metabolite at the primary site in prostate cancer, as a key inducer of dormant state associated with stemness, therapy tolerance, and invasiveness.

[Advanced Healthcare Materials] Investigators developed a CD44-targeted antibody-drug conjugate by conjugating doxorubicin to an anti-CD44 monoclonal antibody which showed promise for targeting CSC-driven ovarian cancer.

[Cell Death Discovery] Scientists showed that AMC303, a highly selective CD44v6 inhibitor, needs to be combined with a PI3K/mTOR inhibitor to prevent or reverse anti-tumor therapeutic resistance and disease progression under tumor microenvironmental cues.

[European Journal of Pharmacology] Researchers investigated the antitumor activity of a recombinant spinach type I ribosome-inactivating protein in HT29 colorectal cancer cells and evaluated its effects on cellular survival, apoptosis, and stemness-associated pathways.

[Scientific Reports] Investigators found that PDLIM1 is markedly upregulated in acute myeloid leukemia and leukemia stem cells and they investigated the molecular functions using an integrated multi-omics framework.

[Scientific Reports] The authors identified a role for cytochrome b5 reductase 1 (CYB5R1) in triple-negative breast cancer progression and epithelial–mesenchymal transition- and stemness-associated phenotypes, mediated partly through STAM2/STAT3 signaling.

[Molecular Biology Reports] Researchers investigated the toxicity of benzo(a)pyrene in the reproductive tract of female Swiss mice, finding disrupted folliculogenesis, reduced ovarian follicle size, epithelial hyperplasia, lymphocytic infiltration, increased vascularisation, atrophied uterine lining, and abnormal glandular growth in the uterus.

[Gene] Scientists synthesize the evidence for epigenetic mechanisms linking oxygen deprivation to stemness, metastasis, and therapy resistance into a unified mechanistic framework.